Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The labeling information of the treatment,
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
USFDA approves Bristol Myers Squibb Cobenfy for Schizophrenia treatment in adults
The landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm,
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the debilitating mental disorder in over seven decades.
Bristol-Myers Squibb’s Cobenfy Launch Spurs ‘Buy’ Rating Amid Favorable Market Dynamics
Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price
16h
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
14h
on MSN
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
IDF: Hezbollah leader killed
Helene: How to help
Houthis attack US warships
Congressional Gold Medal
NC dam failure ‘imminent’
Dow closes at record high
Haney sues Garcia
'Harry Potter' star dies
High-end brothel plea
ICE: Convicts roaming free
Van Gogh paintings attacked
Troops to leave some bases
NY ballot appeal rejected
Meta hit with privacy fine
Deposition in AI suit
Diocese reaches settlement
Promotes watch collection
Bill to use birth control
KY sues Express Scripts
Fed inflation gauge cools
US charges three Iranians
ISR targets Hezbollah HQ
Urgent safety alert for 737s
Ending password-sharing
50/50 ball ownership suit
Fake Biden robocalls fine
Producing doc on Diddy
Killer gets life sentence
Boxes to distribute Narcan
Pleads not guilty
Feedback